Novel non-nucleotidic STING agonists for cancer immunotherapy

Future Med Chem. 2018 Dec;10(24):2767-2769. doi: 10.4155/fmc-2018-0367. Epub 2018 Dec 10.

Authors

Gilles Berger¹, Sean E Lawler²

Affiliations

¹ Faculty of Pharmacy, Microbiology, Bioorganic & Macromolecular Chemistry, Université libre de Bruxelles, Bd du Triomphe, 1050 Brussels, Belgium.
² Department of Neurosurgery, Harvey Cushing Neuro-Oncology Laboratories, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 30526033
DOI: 10.4155/fmc-2018-0367

No abstract available

Keywords: STING; cancer immunotherapy; cyclic dinucleotides.

Publication types

Editorial

MeSH terms

Humans
Immunotherapy*
Membrane Proteins / agonists*
Membrane Proteins / immunology
Membrane Proteins / metabolism
Neoplasms / immunology
Neoplasms / metabolism
Neoplasms / therapy*
Nucleotides, Cyclic / pharmacology*

Substances

Membrane Proteins
Nucleotides, Cyclic
STING1 protein, human